The future looks very bullish for this vaccine specialist. At the beginning of 2020, Novavax (NASDAQ:NVAX) had a valuation of $4 a share. Six months later, the company's stock sells for $47 a share. That's a dramatic shift in perception of value. What's the stock market seeing now that it didn't see in January? In a…
Novavax is well ahead in clinical testing than two of the White House's COVID-19 vaccine finalists. No company has developed a COVID-19 vaccine that's been proven to be safe and effective yet. But several appear to be getting a big boost for their efforts from Uncle Sam. The New York Times reported on Wednesday that…
3 min read This story is part of a series on 10 life-saving medical breakthroughs. Click here to read the rest. ANTONIO TORRES, A 24-year-old from Denver, used to spend six hours each day bathing and meticulously wrapping the red, raw skin along his shoulders and spine. “My wounds take up a large percentage of
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use has recommended granting marketing authorization for Moderna’s new RNA-based vaccine, mNexspike, for preventing COVID-19 in people aged 12 years or older. The vaccine was approved in May 2025 by the US FDA for individuals aged 65 years or older or aged 12-64 years
KFF Health News chief Washington correspondent Julie Rovner discussed Affordable Care Act subsidies on Crooked Media’s What a Day on Dec. 10 and on Slate’s What Next on Dec. 9. Click here to hear Rovner on What a Day. Click here to hear Rovner on What Next. KFF Health News Washington health policy reporter Amanda